Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,182 GBX | -0.52% | -0.85% | +14.72% |
10:04am | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
14/05 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.72% | 24TCr | |
+30.67% | 59TCr | |
-3.42% | 36TCr | |
+18.02% | 33TCr | |
+4.27% | 29TCr | |
+9.77% | 21TCr | |
-7.85% | 20TCr | |
+8.12% | 17TCr | |
-1.42% | 16TCr | |
+1.47% | 12TCr |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Truqap Plus Faslodex Breast Cancer Treatment Bags EU Approval Recommendation